Drug Profile


Alternative Names: AGN-214868; SXN 100323; TEM

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Health Protection Agency Porton Down
  • Developer Allergan
  • Class Bacterial toxins; Endopeptidases; Non-opioid analgesics; Recombinant proteins; Urologics
  • Mechanism of Action SNARE protein antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Postherpetic neuralgia
  • No development reported Overactive bladder

Most Recent Events

  • 14 Oct 2016 Allergan in-licenses RTGel™ technology from Urogen Pharma
  • 23 Jun 2015 No recent reports on development identified - Phase-II for Overactive bladder in USA, France and Netherlands (Intravesicular)
  • 23 Jun 2015 No recent reports on development identified - Phase-II for Postherpetic neuralgia in Czech Republic (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top